P04.10 PREDICTIVE VALUE OF MGMT PROMOTER METHYLATION QUANTITATIVE ASSESSMENT IN GLIOBLASTOMA, WHICH OPTIMAL CUT-POINT?

MLA

de Saint-Denis, T., et al. “P04.10 Predictive Value of Mgmt Promoter Methylation Quantitative Assessment in Glioblastoma, Which Optimal Cut-Point?” Neuro-Oncology, vol. 16, no. suppl_2, Sept. 2014, pp. ii38-ii39. EBSCOhost, https://doi.org/10.1093/neuonc/nou174.142.

APA

de Saint-Denis, T., Lerhun, E., Ramirez, C., Devos, P., Maurage, C. A., Dubois, F., Reyns, N., & Escande, F. (2014). P04.10 Predictive Value of Mgmt Promoter Methylation Quantitative Assessment in Glioblastoma, Which Optimal Cut-Point? Neuro-Oncology, 16(suppl_2), ii38-ii39. https://doi.org/10.1093/neuonc/nou174.142

Chicago

de Saint-Denis, T., E. Lerhun, C. Ramirez, P. Devos, C.A. Maurage, F. Dubois, N. Reyns, and F. Escande. 2014. “P04.10 Predictive Value of Mgmt Promoter Methylation Quantitative Assessment in Glioblastoma, Which Optimal Cut-Point?” Neuro-Oncology 16 (suppl_2): ii38-ii39. doi:10.1093/neuonc/nou174.142.